We are analyzing https://link.springer.com/chapter/10.1007/978-1-4614-4732-0_11.

Title:
Antibodies as Cancer Immunotherapy | SpringerLink
Description:
Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

google, scholar, pubmed, article, cas, cancer, clin, patients, oncol, phase, antibody, metastatic, growth, antibodies, monoclonal, treatment, receptor, study, factor, human, therapy, res, trial, clinical, med, colorectal, bevacizumab, cell, breast, immunotherapy, advanced, epidermal, iii, survival, tumor, rituximab, immunol, cetuximab, nat, rev, lymphoma, blood, combination, randomized, chapter, targeting, results, biol, therapeutic, engl,

Topics {✒️}

yttrium-90-labeled anti-carcinoembryonic antigen 131i-a5b7 anti-cea antibody adult t-cell leukemia-lymphoma diffuse large-b-cell lymphoma cancer-related anorexia/cachexia syndrome anti-plgf inhibits growth epidermal growth factor anti-muc1 antibody as1402 anti-cd52 monoclonal antibody anti-cd20 monoclonal antibody month download article/chapter peripheral t-cell lymphoma folate receptor-targeted therapeutics neu differentiation factor/neuregulin tumour necrosis factor anti-cd20 antibody immunotherapy potent labetuzumab-sn-38 immunoconjugates facilitate breast-tumour metastasis oxidized mannan-muc1 [isrctn71711835] growth factor receptors anti-egfr targeted drugs small-cell lung cancer fc receptor-dependent mechanisms successful immune-based agents egfr-targeted monoclonal antibodies cea-producing advanced malignancies tyrosine kinase inhibition inhibitor-resistant tumors chronic lymphocytic leukemia blood–brain barrier disruption antibody targeting trail-r1 fully human antibodies humanized monoclonal antibody refractory multiple myeloma response-independent survival benefit human breast cancer fibroblast activation protein human monoclonal antibodies monoclonal antibody production indolent multiple myeloma anti-cardiolipin idiotype t-cell lymphomas cd30-positive malignancies cancer-related inflammation endothelial cell survival alphavbeta3 integrin receptor current fda-approved antibodies egf receptor family b-cell malignancies metastatic breast cancer

Questions {❓}

Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Silverstein AM (2002) The collected papers of Paul Ehrlich: why was volume 4 never published?

Schema {🗺️}

ScholarlyArticle:
      headline:Antibodies as Cancer Immunotherapy
      pageEnd:376
      pageStart:335
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4614-4732-0.jpg
      genre:
         Biomedical and Life Sciences
         Biomedical and Life Sciences (R0)
      isPartOf:
         name:Cancer Immunotherapy
         isbn:
            978-1-4614-4732-0
            978-1-4614-4731-3
         type:Book
      publisher:
         name:Springer New York
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Devalingam Mahalingam
            affiliation:
                  name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
                  address:
                     name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tyler J. Curiel
            affiliation:
                  name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
                  address:
                     name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      keywords:Epidermal Growth Factor Receptor, Human Epidermal Growth Factor Receptor, Chronic Lymphocytic Leukemia, Metastatic Colorectal Cancer, KRAS Mutation
      description:Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12 . Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.
      datePublished:2013
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Cancer Immunotherapy
      isbn:
         978-1-4614-4732-0
         978-1-4614-4731-3
Organization:
      name:Springer New York
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
      address:
         name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
      address:
         name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Devalingam Mahalingam
      affiliation:
            name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
            address:
               name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Tyler J. Curiel
      affiliation:
            name:University of Texas Health Science Center, Adult Cancer Program, STRF MC8252
            address:
               name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
      name:Cancer Therapy & Research Center, University of Texas Health Science Center, Adult Cancer Program, STRF MC8252, San Antonio, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(631)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

CDN Services {📦}

Pbgrd

6.01s.

LINK . SPRINGER . COM {}